EUVIMEDOpdag EUVIMED
Video/Audio

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Rakan El-Mayta, Marshall S Padilla, Margaret M Billingsley, Xuexiang Han, Michael J Mitchell

Journal of Visualized Experiments · 2023

DOI: 10.3791/64810 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2023. Written by Rakan El-Mayta and 4 co-authors. Institution: Department of Bioengineering, University of Pennsylvania. Major MEDLINE topics: COVID-19, Nanoparticles. Cited 17 times so far (Crossref); 40 references. Funded by: NCATS NIH HHS, NCI NIH HHS, NIDDK NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Lipid nanoparticles (LNPs) have attracted widespread attention recently with the successful development of the COVID-19 mRNA vaccines by Moderna and Pfizer/BioNTech. These vaccines have demonstrated the efficacy of mRNA-LNP therapeutics and opened the door for future clinical applications. In mRNA-LNP systems, the LNPs serve as delivery platforms that protect the mRNA cargo from degradation by nucleases and mediate their intracellular delivery. The LNPs are typically composed of four components: an ionizable lipid, a phospholipid, cholesterol, and a lipid-anchored polyethylene glycol (PEG) conjugate (lipid-PEG). Here, LNPs encapsulating mRNA encoding firefly luciferase are formulated by microfluidic mixing of the organic phase containing LNP lipid components and the aqueous phase containing mRNA. These mRNA-LNPs are then tested in vitro to evaluate their transfection efficiency in HepG2 cells using a bioluminescent plate-based assay. Additionally, mRNA-LNPs are evaluated in vivo in C57BL/6 mice following an intravenous injection via the lateral tail vein. Whole-body bioluminescence imaging is performed by using an in vivo imaging system. Representative results are shown for the mRNA-LNP characteristics, their transfection efficiency in HepG2 cells, and the total luminescent flux in C57BL/6 mice.

Subjects

MeSH terms (MEDLINE)

COVID-19NanoparticlesAnimalsMiceRNA, MessengerMicrofluidicsMice, Inbred C57BLPhospholipidsRNA, Small InterferingLiposomes

Substances

RNA, MessengerPhospholipidsRNA, Small InterferingLipid NanoparticlesLiposomes

Authors and institutions

  • Department of Bioengineering, University of Pennsylvania.
  • Department of Bioengineering, University of Pennsylvania; mjmitch@seas.upenn.edu.

Funding

  • NCATS NIH HHS
  • NCI NIH HHS
  • NIDDK NIH HHS

Cite

APA

El-Mayta, R., Padilla, M. S., Billingsley, M. M., Han, X., & Mitchell, M. J. (2023). Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing. Journal of Visualized Experiments. https://doi.org/10.3791/64810

Vancouver

El-Mayta R, Padilla MS, Billingsley MM, Han X, Mitchell MJ. Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing. Journal of Visualized Experiments. 2023. doi:10.3791/64810

BibTeX
@article{ElMayta2023,
  author = {El-Mayta, Rakan and Padilla, Marshall S and Billingsley, Margaret M and Han, Xuexiang and Mitchell, Michael J},
  title = {Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing},
  journal = {Journal of Visualized Experiments},
  year = {2023},
  doi = {10.3791/64810}
}
Start for free →